Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive...

MONDAY, Oct. 28, 2024 -- From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium...

Ozempic and other GLP-1 drugs show promise not only in managing obesity and diabetes but also in reducing Alzheimer's risk. A study published in...

TUESDAY, Oct. 29, 2024 -- Among privately insured patients, there was a doubling in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs)...

Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing elective surgery and...

FRIDAY, Nov. 1, 2024 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer...

FRIDAY, Nov. 1, 2024 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer...

FRIDAY, Oct. 25, 2024 -- For patients with opioid use disorder (OUD) and alcohol use disorder (AUD), prescriptions of glucose-dependent insulinotropic...

Type 2 diabetes affects 1.2 million Australians and accounts for 85-90% of all diabetes cases. This chronic condition is characterised by high blood...

The rise in type 2 diabetes has become a significant public health concern in recent years. This form of diabetes happens when the body struggles to...